Talk:Institute for Clinical and Economic Review
 | This article has not yet been rated on Wikipedia's content assessment scale. |
Possible updates[edit]
2017: It has issued a draft report on PARP inhibitors for ovarian cancer. [1] also says "The group recently said osteoporosis meds from Radius and Eli Lilly are far too expensive. Before that, it concluded most multiple sclerosis drugs on the market are overpriced. It’s also hit at pharma’s pricing for PCSK9 cholesterol meds, immuno-oncology therapies and other drug classes. Pharma has hit back by blasting the nonprofit's review methods.
In response to the criticism, ICER last year convened a discussion with a broad group of players to change its assessment methods. Afterward, the group broadened its quality-adjusted life year threshold to $50,000 to $150,000 and committed to reviewing drugs at their price minus rebates, among other changes." - Rod57 (talk) 11:45, 22 July 2017 (UTC)
--
2021: This page is slightly confusing because there are criticism of ICER's methodology in the middle of the Threshold Cost Criteria. It also appears as though the methodology is slightly out-of-date as much of it was changed in 2020. This page could be improved by updating the Threshold Cost Criteria section with the most recent methodology and then consolidating the criticism into a stand-alone section. Dibedits (talk) 22:44, 30 March 2021 (UTC)